

New York State Journal of Medicine (ISSN 0025-7628)

Published monthly with the Minutes of the House of Delegates added in March by the Medical Society of the State of New York. Copyright 1981 by the Medical Society of the State of New York. All material covered in the New York State Journal of Medicine may be photocopied for noncommercial scientific or educational use only. Special arrangements and permission are required from the author(s) of the particular article and from the editor for any other purpose. Editorial, Circulation, and Advertising Offices: 420 Lakeville Rd., Lake Success, N.Y. 11042. Change of Address: Notice should state whether or not change is permanent and should include the old address. Six weeks notice is required to effect a change of address. Fifty cents per copy—\$3.50 per year. Foreign subscriptions: \$3.50 subscription plus \$1.50 for mailing. Second-class postage paid at New Hyde Park, N.Y., and additional mailing office. POSTMASTER: Send POD form 3579 to New York State Journal of Medicine, 420 Lakeville Rd., Lake Success, N.Y. 11042.

Contents

MARCH 1981

VOLUME 81

NUMBER 3

The Editors of the Journal assume no responsibility for opinions and claims expressed in the articles contributed by individual authors. Contributions accepted for original publication only.

Scientific Articles

- 321 **Campylobacter Fetus Jejuni Enteritis in New York City**
Anne C. Masenthal, B.A., Richard L. Mones, M.D., and Victor D. Bokkenheuser, M.D.
- 324 **Extrahepatic Bile Duct Cancer**
Edith D. Greenwald, Edward S. Greenwald, M.D., and Stephen M. Brenner, M.D.
- 327 **Percutaneous Endoscopic Extraction Retained Stones: endoscopic extraction from common bile duct and gallbladder**
Jerome H. Siegel, M.D., G. Thomas Harding, M.D., Frank Chateau, P.A.-C., Howard J. Sherman, M.D., Carter Davis, Jr., M.D., and William A. Webb, M.D.
- 331 **Cervical Cancer Screening: need among hospital inpatients**
John Boyce, M.D., F.A.C.O.G., Rachel Fruchter, Ph.D., Mary Thompson, R.N., Claudia Conly, R.N., Mendis Jones, R.N., Juan Maloney, R.N., and Randall Bloomfield, M.D., F.A.C.O.G.
- 336 **Metastatic Carcinoma: insensitivity of buffy coat preparations**
Jonathan Rubins, M.D., Virginia Adams, M.S., M.T., (A.S.C.P.) S.H., Judith Winchester, H. (A.S.C.P.), and Judith E. Woll, M.D.
- 339 **Lung Cancer: preoperative radiation therapy and surgery**
Paul A. Kirschner, M.D., F.A.C.S., F.C.C.P.
- 343 **Blood Grouping Tests for Paternity and Nonpaternity**
Leon N. Sussman, M.D., and Bal K. Gilja, M.D.

Electrocardiograms of the Month

- 347 **Questions 311 and 312**
Ira L. Rubin, M.D., and Julian Frieden, M.D., Editors

Radiologic Problem of the Month

- 349 **Acute Abdomen**
Kakarla Subbarao, M.D.

Case Reports

- 351 **Volume Receptor Control of ADH Release in Essential Hypernatremia**
Steven Jay Rosansky, M.D., and Bernard D. Nidus, M.D.
- 357 **Splenorrhaphy: successful application in prematurity**
Neil D. Kutin, M.D., Rolando Sanchez, M.D., and Madhu Bhogal, M.D.
- 360 **Pelvic Cecum: cause of signs and symptoms**
Andreas Koutros, M.D., F.A.A.P., and John P. Curran, M.D.
- 362 **Bernard-Horner Syndrome: associated with Swan-Ganz catheter**
Richard B. Burrer, M.D., and Charles M. Plotz, M.D., Med.Sc.D.
- 365 **Pseudoaneurysm of Aortic Stump: rupture in pregnancy**
Stephen Matseoane, M.D., F.A.C.S., F.A.C.O.G., Harold Freeman, M.D., F.A.C.S., Johnny Williams, M.D., Ganepola Ganepola, M.D., F.A.C.S., and Samuel Brisbane, M.D.
- 368 **Tuberculosis of Myocardium**
Michael K. Jason, M.D., Samuel Zonerach, M.D., F.A.C.C., and Gertrude Silverman, M.D.
- 372 **Metastasizing Fibroleiomyoma**
Harry Steinberg, M.D., Robert Chait, M.D., James Sciubba, D.M.D., Ph.D., Belinde Aftalion, M.D., and George Pillari, M.D.
- 376 **Extragenital Germ-Cell Cancer Syndrome**
Patrick R. Bergevin, M.D., Sandra Harris-Corrado, M.D., Yvonne Lamy, M.D., and Raul Alessandri, M.D.

Extrahepatic Bile Duct Cancer

EDITH D. GREENWALD,^a

New York, New York

EDWARD S. GREENWALD, M.D.^b

The Bronx, New York

STEPHEN M. BRENNER, M.D.^c

The Bronx, New York

^a Graduate Assistant, Institute of Environmental Medicine, New York University Medical Center.

^b Acting Chief, Department of Oncology, Montefiore Hospital and Medical Center.

^c Adjunct, Division of Gastroenterology, Department of Medicine, Montefiore Hospital and Medical Center

This review was undertaken after one of the authors (S.M.B.) noted an increased incidence of extrahepatic bile duct cancer at Montefiore Hospital and Medical Center. Although the etiology of this uncommon tumor is not known, one hypothesis is that extrahepatic bile duct cancer may be caused by a carcinogen in the bile, either ingested or inhaled, or a transformation product of an ingested or inhaled substance.

At Montefiore Hospital and Medical Center the number of cases of extrahepatic bile duct cancer reported was:

Before 1960	7
1960-65	10
1965-70	12
1970-75	20
Jan. 1, 1976, to Dec. 31, 1979	19

Possible explanations for this increase are: (1) increased diagnostic skills resulting in more diagnoses; (2) referral of cases to a large center; and (3) a true increase in incidence. It is unlikely that the second hypothesis is true because almost all patients were self referred to Montefiore Hospital and Medical Center or to its affiliated physicians.

Incidence

All authors agree that tumors of the biliary tract are comparatively rare, although there is a possibility of significant underreporting because of difficulties in both macroscopic and microscopic diagnosis. There is a 2:3 female-to-male ratio, with the age-

adjusted incidence rate generally higher in whites. The age range is wide, with peak incidence in the sixth decade in several series.¹ Incidence is significantly higher in American Indians,^{2,3} in the Mexican population in the southwestern part of the United States,⁴ and in Japanese migrants to the United States.⁵

The incidence of cancer of the extrahepatic bile ducts may be expressed in several ways. In a review of 12 autopsy series published in 1957,⁶ there was a variation in incidence from 0.012 percent to 0.458 percent, while carcinomas were found in 0.3 percent and 1.8 percent of all biliary tract operations performed in 2 series. As a percentage of all hospital admissions, cancer of the extrahepatic biliary tract accounted for 0.007 to 0.041 percent of the total figure.

The National Cancer Institute's Third National Cancer Survey⁷ estimated 11,800 new cases of carcinoma of the liver and biliary passages in 1976, while the U.S. government vital statistics report for 1976⁸ listed 4,276 deaths due to malignant lesions of the biliary passages. If 40 percent of the anticipated new cases of liver and bile passage malignant neoplasms during 1976 are bile duct carcinomas, approximately 4,500 new cases can be expected in this country in 1980.

The average annual crude incidence rate from 1969 through 1971 for biliary tract cancer in the United States is 1.2 per 100,000, while the average annual age-adjusted incidence rate (1970 standard) is 1.3 per 100,000.⁷ It is difficult to ascertain a trend because, while the Third National Cancer Survey⁷ classifies gallbladder cancer separately from other biliary tract neoplasms, which are primarily extrahepatic bile duct carcinomas, in previous cancer surveys data for gallbladder cancer and other biliary tract neoplasms were lumped together. Another handicap is the failure of the International Classification of Diseases to distinguish between cancers of the liver and the biliary system until the seventh revision in 1958.

Many authorities believe that gallstones are etiologically related to bile duct cancer. Data published by Stewart, Lieber, and Morgan,⁹ Neibling, Dockerty, and Waugh,¹⁰ Sako, Seitzinger, and Garside,⁶ and Ross, Braasch, and Warren¹¹ have shown that gallstones are associated with 20 to 57 percent of such cancers. Although, on the average, gallstones are found in about one third of patients with bile duct cancer, this fact is of unknown significance.

Biliary tract carcinoma is possibly 10 times more frequent in patients with ulcerative colitis than in the general population.¹² A series of 13 patients with bile duct cancer (excluding gallbladder cancer) and associated chronic ulcerative colitis seen at the Mayo Clinic from 1935 to 1973¹³ and a review of the literature suggest that the relationship between chronic ulcerative colitis and bile duct cancer is not just a chance occurrence. The carcinoma has an onset approximately three decades earlier than cancer of the bile ducts without chronic ulcerative colitis, and

neither surgical removal of the diseased colon, mode of medical management of the unresected colon, nor extent or severity of the colonic disease have any relationship to the subsequent development of cancer of the bile ducts.¹³ However, no mechanism of causation is apparent, and "it would appear that biliary tract cancer is another member of the spectrum of hepatic disorders that may occur in patients with ulcerative colitis, but which progress independently of the colonic disease."¹³

There is a strong association of bile duct carcinoma with congenital biliary tract cysts (choledochal cysts). This may result from interaction between chronic inflammation and carcinogenic substances excreted in the bile. The presence of a cyst could lead to bile duct stasis with resultant prolonged exposure of the mucosa to bile.¹⁴

Studies of vinyl chloride workers have shown a much higher rate of liver and biliary tract cancer than that expected, but, unfortunately, the significance of these data could not be ascertained because extrahepatic biliary tract cancer was not classified separately.^{15,16}

In 1970, an epidemiologic survey of rubber workers suggested an excess of cancer of the gallbladder and bile ducts.¹⁷ There was also a shift in age distribution to younger groups, which would support association with employment. Occupational mortality statistics from California demonstrate that gallbladder and bile duct cancers are prominent among automotive and rubber plant workers, while bile duct cancers show increased incidence in workers in the aircraft, chemical, and wood finishing industries.¹⁸

Chemical factors

Laboratory animals have been used to demonstrate the excretion in the bile of experimental carcinogens or their metabolites, with associated concentration in the bile and gallbladder. A number of chemicals tested by animal bioassay have produced biliary tract changes, proliferation of bile ducts, bile duct hypertrophy, cholangiomas, cholangiocarcinomas, and carcinomas in the bile ducts.

A number of complex chemicals used in the rubber industry, including nitrosamine compounds, benzidine, Flectol H, and M-toluylenediamine were shown by investigators to be injurious to the hepatobiliary system. Rats fed Flectol H, a polymer of 1-2 dihydro-2,2,4-trimethyl quindine, developed biliary tract hyperplasia, atypical proliferation of the biliary ducts and of fibrous tissue, and cholangiofibrosis, considered a precursor to biliary duct carcinoma. Oral administration of M-toluylenediamine induced proliferation of the bile ducts, followed by carcinoma. Cyclohexylamine, a carcinogenic metabolic product of cyclamates, is also used in the rubber industry. Therefore, many investigators conclude that certain chemicals are an etiologic factor in the development of carcinoma of the bile ducts among rubber workers.¹⁷

An increased number of self-referred patients with extrahepatic bile duct cancer have been seen at Montefiore Hospital and Medical Center in the last ten years. Although improved diagnostic methods may partially explain this phenomenon, actual increased incidence is suggested. The literature is reviewed for known causative factors in extrahepatic bile duct cancer. Transhepatic cholangiography, routinely carried out in extrahepatic bile duct cancer patients, would be a good source of bile for study of carcinogenic and mutagenic activity.

Daily oral doses of the pesticide aramite led to the production of gallbladder and bile duct carcinoma in dogs in at least one experiment.¹⁵ Two dogs who were fed 8-aminoazotoluene, one for 30 months and the second for 62 months, developed adenocarcinomas involving the entire biliary tract which resembled the diffuse involvement of the biliary tract by cancer in human beings.¹⁹ Mice fed cholesterol, cholic acid, and the carcinogen 2-acetamidofluorene or its N-hydroxy derivative developed proliferation of mucosa in the extrahepatic bile duct, atypical cells in the mucosal epithelium of the bile duct, and, occasionally, adenocarcinoma of the common bile duct. Metabolites of the carcinogen and its derivative were found in the bile of these mice.²⁰

Some investigators believe that the typical American diet of 45 percent fat results in the excretion of large quantities of bile acids which may act as cocarcinogens.²¹ People who eat large quantities of smoked food or work in meat-smoking factories have a particularly high incidence of digestive cancers, possibly caused by polycyclic aromatic hydrocarbons and/or N-nitrosamines. Nitrites and secondary amines present in food and nitrates and nitrites added as preservatives react to form N-nitrosamines under mild conditions of temperature and pH. N-nitrosamines have been implicated in cancer causation in a wide variety of animals and in virtually every organ in the rat, and it is therefore postulated that man is also sensitive to these compounds.²²

The carcinogenic action of aflatoxins, metabolites of some strains of *Aspergillus flavus*, has been studied in fish, birds, and mammals. Although the liver was the organ most affected in all species, marked intrahepatic bile duct proliferation, possibly representing a premalignant lesion, was noted in the rat, duckling, chicken, cattle, monkey, guinea pig, dog, and trout. Cholangiocarcinoma in the intrahepatic bile duct was seen in one rat, while bile duct hyperplasia occurred in the rabbit and in the cat. It is assumed that aflatoxin in the bile may be a factor in the production of bile duct proliferation and occasional areas of fibrosis. Although there is now no direct evidence that man is susceptible to aflatoxins, their demonstrated carcinogenicity in a broad spectrum of animals make them suspect as a hazard to

Specific carcinogens could be isolated, and bile could be studied for distribution patterns of bile acids and their conjugates.

Department of Oncology
Montefiore Hospital and Medical Center
111 East 210th Street
Bronx, New York 10467
(DR. E. S. GREENWALD)

1. Longmire, W. P., Jr.: Tumors of the extrahepatic biliary radicals. *Curr. Probl. Cancer* 1: 5 (1976).
2. Rudolph, R., Cohen, J. J., and Gascoigne, R. H.: Biliary cancer among Southwestern American Indians. *Arizona Med.* 27: 1 (1970).
3. Dunham, L. J., Bailer, J. C., III, and Laqueur, G. L.: Histologically diagnosed cancers in 693 Indians of the United States, 1950-65. *J. Nat'l Cancer Inst.* 50: 1119 (1973).
4. Bornstein, F. P.: Gallbladder carcinoma in the Mexican population of the Southwestern United States. *Path. Microbiol.* 35: 189 (1970).
5. Krain, L. S.: Gallbladder and extrahepatic bile duct carcinoma. Analysis of 1,808 cases. *Geriatrics* 27: 111 (1972).
6. Sako, K., Seitzinger, G. L., and Garside, E.: Carcinoma of the extrahepatic bile ducts: review of the literature and report of six cases. *Surgery* 41: 416 (1957).
7. Third National Cancer Survey Incidence Data. Monograph 41. Biometry Branch. Nat'l Cancer Institute, 1975.
8. Vital Statistics of the United States, 1959. Monograph, Department of Health, Education, and Welfare, Washington, D.C., U.S. Government Printing Office, 1961, vol. 2, table 74, p. 114.
9. Stewart, H. L., Lieber, M. M., and Morgan, D. R.: Carcinoma of the extrahepatic bile ducts. *Arch. Surg.* 41: 6 (1940).
10. Niebling, H. A., Dockerty, M. B., and Waugh, J. M.: Carcinoma of the extrahepatic bile ducts. *Surg. Gynec. & Obst.* 88: 429 (1949).
11. Ross, A. P., Braasch, J. W., and Warren, K. W.: Carcinoma of the proximal bile ducts. *ibid.* 136: 923 (1973).
12. Ritchie, J. K., et al.: Biliary tract carcinoma associated with ulcerative colitis. *Quart. J. Med.* 43: 263 (1974).
13. Akwari, O. E., Van Heerden, J. A., Foulk, W. T., and Bagenstoss, A.: Cancer of the bile ducts associated with ulcerative colitis. *Ann. Surg.* 181: 303 (1975).
14. Bismuth, H., and Malt, R. A.: Current concepts in cancer: carcinoma of the biliary tract. *New England J. Med.* 301: 704 (Sept. 27) 1979.
15. Monson, R. R., Peters, J. M., and Johnson, M. N.: Proportional mortality among vinyl-chloride workers. *Lancet* 2: 357 (1974).
16. Waxweiler, R. J., Stringer, W., Wagoner, J. K., and Jones, J.: Neoplastic risk among workers exposed to vinyl chloride. *Ann. New York Acad. Sci.* 271: 40 (1976).
17. Mancuso, T. F., and Brennan, M. J.: Epidemiological considerations of cancer of the gallbladder, bile ducts and salivary glands in the rubber industry. *J. Occup. Med.* 12: 333 (1970).
18. Gallagher, P. J., Millis, R. R., and Mitchinson, M. J.: Congenital dilatation of the intrahepatic bile ducts with cholangiocarcinoma. *J. Clin. Path.* 25: 804 (1972).
19. Fraumeni, J. J., Jr.: Cancers of pancreas and biliary tract: epidemiological considerations. *Cancer Res.* 35: 3437 (1975).
20. Enomoto, M., et al.: Carcinogenesis in extrahepatic bile duct and gallbladder—carcinogenic effect of N-hydroxy-2-acetylaminofluorene in mice fed a "gallstone-inducing" diet. *Jap. J. Exp. Med.* 44: 34 (1974).
21. Vitale, J. J.: Possible role of nutrients in neoplasia. *Cancer Res.* 33: 3320 (1975).
22. Sinhuber, R.: Food contaminants and carcinogenesis, in Clark, R., Ed.: *Oncology*. Chicago, Year Book Medical Publishers, 1971, vol. 5, p. 257.
23. Newburne, P. M., and Butler, W. H.: Acute and chronic effects of aflatoxin on the liver of domestic and laboratory animals: a review. *Cancer Res.* 29: 235 (1969).

From
Med
Med
Univ
Grav
of M
Ope
tial

The
sur
con
gall
oth
This
app
mor
been
per
man
servo
PE
the
31
be
the
two
the
and
hee
PE
part
add
serv
the
Lib